A Phase 2 interventional study of Belumosudil and Placebo in Chronic Plaque Psoriasis, sponsored by Kadmon Corporation, LLC. Completed at 14 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-16.
Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.
Among the 202 studies in Skin Diseases with a site in United States, this one is the 84th largest by enrollment of the 172 interventional ones that give a count, is one of 10 that started in 2016, is one of 63 in phase 2, and was the 65th registered.
497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.
Browse Skin Diseases studies →32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:
IAS Skin Care · Sites in United States
Ages 25–65 · Women only · Healthy volunteers
WiQo S.p.A. · Sites in United States
Ages 18+ · Healthy volunteers
Spyre Therapeutics, Inc. · Sites in United States, Canada
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 69 · Phase 3 46 · Phase 4 8
First in 1978; this study’s year is marked. 10 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 70 across 375 interventional studies indexed under Skin Diseases.
Median enrollment 99 across the 172 interventional studies, 298 across the 28 observational. Of the 142 that completed or were terminated, 90 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
139 of 202 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kadmon Corporation, LLC, one of the names counted as Sanofi. Under that name alone:
Kadmon Corporation, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.
Sanofi has 3 studies filed under Skin Diseases — fewer than ten, so there is no comparison to draw.
19 of the studies in Skin Diseases with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144345Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | 2027-01 |
| NCT07144852Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | 2027-01 |
| NCT07717346Krystal Biotech, Inc.A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease | 2026-11 |
| NCT06674980C5 BiomedicalClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs | 2026-11-22 |
| NCT07866131WiQo S.p.A.Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin | 2026-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 202 studies in Skin Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
This phase 2, two-period, dose-finding, placebo-controlled study is performed on adult male and female subjects to evaluate the efficacy and safety of subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Period 1: Double-blind, Placebo-controlled Treatment Period
Approximately 110 subjects are planned to be randomly assigned to each of 5 dose cohorts in a 1:1:1:1:1 manner. Each cohort is planned to have 22 subjects who meet eligibility criteria. Subjects are treated with oral (PO) belumosudil tablets or placebo tablets as follows:
Subjects in each of the 5 cohorts in Period 1 are treated with study medication for a period of 16 weeks.
Note: Originally, a sample size of 36 subjects per cohort was planned to provide approximately 90% probability ≥ 1 subject in the 5 cohorts would experience an adverse event (AE) that had an underlying rate of ≥ 6% and approximately an 80% probability of ≥ 1 subject in the cohort experiencing an AE that had an underlying rate of ≥ 4%. However, due to a newly available plaque psoriasis treatment, the study is terminated early with 110 subjects.
Period 2: Open-label Treatment Period (with Belumosudil)
All subjects treated for 16 weeks, regardless of treatment with belumosudil (Cohorts 1 through 4) or placebo (Cohort 5) are given the option to receive 400 mg belumosudil QD for an additional 32 weeks (Week 16 through Week 48).
Follow-up Period
All subjects have a safety evaluation 30 days after the last dose of study drug.
Efficacy is assessed by the following scores at scheduled time points throughout the study:
Safety is assessed by;
The maximum duration for subjects who complete Period 1 (Double-blind, Placebo-controlled) is 24 weeks (up to 4-week Screening, 16-week Period 1 treatment, and 4-week Follow-up). The maximum duration for subjects who complete Period 2 (Open-label) is 56 weeks (up to 4-week Screening, 16-week Double-blind Treatment Period, 32-week Open-label Treatment Period, and 4-week Follow-up).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate bone marrow function:
Adequate safety laboratory values:
Female subjects of with a negative pregnancy test at screening. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had any evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, antiestrogens, or ovarian suppression
Exclusion Criteria:
History or presence of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening
Drug: Belumosudil · Drug: Placebo
One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening
Drug: Belumosudil · Drug: Placebo
Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening
Drug: Belumosudil · Drug: Placebo
Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening
Drug: Belumosudil
Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening
Drug: Placebo
Also known as: Rezurock (brand name), KD025
Placebo tablets matching belumosudil
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and Observed
The percentage of subjects who exhibited a 75% decrease or greater in the Psoriasis Area and Severity Index Score (PASI 75) whether they completed 16 weeks of treatment or not (last observation carried forward \[LOCF\]) and those who did complete 16 weeks of treatment (observed). \[PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
Time frame: 16 weeks
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and Observed
The mean change in the raw Psoriasis Area and Severity Index (PASI) score from baseline score to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward \[LOCF\]), or for only those subjects who completed 16 and 48 weeks (observed), respectively. Negative values represent favorable results; positive values represent unfavorable results. \[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
Time frame: 48 weeks
Efficacy: Percentage Change in Mean PASI Score From Baseline to Week 16 and to Week 48--LOCF and Observed
The percentage (%) change in the mean Psoriasis Area and Severity Index (PASI) score from baseline ore to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward \[LOCF\]) or for only those subjects who completed 16 and 48 weeks (observed), respectively. \[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
Time frame: 48 weeks
Efficacy: Number of Subjects With Clear or Almost Clear PGA at Week 16--LOCF
The number of subjects who had a "Clear" or "Almost Clear" assessment, using the Physician Global Assessment Scale (PGA), at Week 16 of all subjects whether they completed 16 weeks or not (last observation carried forward \[LOCF\]) \[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.\]
Time frame: 16 weeks
Efficacy: Percentage of Subjects With Clear or Almost Clear PGA Comparing Belumosudil to Placebo at Week 16--LOCF
The percentage (%) of subjects who had a "Clear" or "Almost Clear" assessment using the Physician Global Assessment Scale at Week 16 of belumosudil vs. placebo for all subjects whether they completed 16 weeks or not (last observation carried forward \[LOCF\]). \[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.\]
Time frame: 16 weeks
Efficacy: Change in Mean DLQI Raw Score at Week 16 and at Week 48
Changes in mean Dermatology Life Quality Index (DLQI) score from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment). \[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. DLQI scoring as measured on subject's life: 0-1 = no effect; 2-5 = small effect; 6-10 = moderate effect; 11 to 20 = very large effect; 21 to 30 = extremely large effect. Change \< 0% is improvement; \> 0% is worsening. The total rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.\]
Time frame: Up to 48 weeks
Efficacy: Percentage Change of Mean DLQI Score From Baseline to Week 16 and Week 48
Mean percentage changes in Dermatology Life Quality Index (DLQI) from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment). \[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.\]
Time frame: Up to 48 weeks
Safety: Number of Subjects With TEAEs, SAEs, and Deaths Throughout the Study
The number of subjects who had treatment-emergent adverse events (TEAEs), severity of TEAEs, relationship of TEAEs to study medication, serious TEAEs (SAEs), dose interruption, discontinuations, and deaths. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = Death. Related to study medication is defined as possible related, probable related, and related
Time frame: Approximately 52 weeks: up to 48 weeks of treatment and 30-day follow-up
| Milestone | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo |
|---|---|---|---|---|---|
| Started | 23 | 22 | 21 | 26 | 18 |
| Completed period 1: double-blind | 14 | 15 | 17 | 16 | 10 |
| Completed period 2: open-label | 11 | 8 | 13 | 11 | 14 |
| Completed | 9 | 6 | 9 | 4 | 2 |
| Not completed | 14 | 16 | 12 | 22 | 16 |
| Withdrew: Adverse event | 3 | 1 | 0 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 3 | 4 | 4 |
| Withdrew: Withdrawal by subject | 6 | 12 | 7 | 10 | 10 |
| Withdrew: Sae | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Elevated liver enzymes | 2 | 0 | 0 | 2 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Dispensing drug violation | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Inclusion/exclusion violation | 1 | 0 | 0 | 0 | 0 |
The percentage of subjects who exhibited a 75% decrease or greater in the Psoriasis Area and Severity Index Score (PASI 75) whether they completed 16 weeks of treatment or not (last observation carried forward \[LOCF\]) and those who did complete 16 weeks of treatment (observed). \[PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
| Percentage of participants | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | All Belumosudil |
|---|---|---|---|---|---|---|
| LOCF (%) | 8.7 (1.1 to 28.0) | 9.1 (1.1 to 29.2) | 19.0 (5.4 to 41.9) | 7.7 (0.9 to 25.1) | 16.7 (3.6 to 41.4) | 10.9 (5.3 to 19.1) |
| Observed (%) | 7.1 (0.2 to 33.9) | 13.3 (1.7 to 40.5) | 23.5 (6.8 to 49.9) | 12.5 (1.6 to 38.3) | 30.0 (6.7 to 65.2) | 14.5 (6.9 to 25.8) |
The mean change in the raw Psoriasis Area and Severity Index (PASI) score from baseline score to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward \[LOCF\]), or for only those subjects who completed 16 and 48 weeks (observed), respectively. Negative values represent favorable results; positive values represent unfavorable results. \[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
| Score on a scale | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | All Belumosudil |
|---|---|---|---|---|---|---|
| Baseline | 18.93 ± 8.31 | 20.60 ± 8.27 | 18.82 ± 6.08 | 19.80 ± 9.03 | 20.72 ± 8.08 | 19.55 ± 7.97 |
| Change at Week 16--LOCF | -5.69 ± 8.59 | -4.49 ± 7.44 | -5.0 ± 8.31 | -4.63 ± 8.04 | -5.68 ± 12.31 | -4.96 ± 7.98 |
| Change at Week 16--Observed | -3.75 ± 8.62 | -6.29 ± 6.45 | -4.96 ± 8.72 | -3.81 ± 5.37 | -8.44 ± 15.36 | -4.71 ± 7.31 |
| Change at Week 48--LOCF | -3.85 ± 10.53 | -6.38 ± 5.16 | -9.01 ± 7.63 | -0.83 ± 7.73 | -9.56 ± 18.98 | -5.11 ± 8.45 |
| Change at Week 48--Observed | -5.93 ± 11.26 | -5.30 ± 5.88 | -12.99 ± 6.71 | -4.27 ± 2.16 | 9.45 ± 21.00 | -7.98 ± 8.76 |
The percentage (%) change in the mean Psoriasis Area and Severity Index (PASI) score from baseline ore to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward \[LOCF\]) or for only those subjects who completed 16 and 48 weeks (observed), respectively. \[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
| Percentage Change in PASI Score | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | All Belumosudil |
|---|---|---|---|---|---|---|
| Change (%) at Week 16--LOCF | -27.17 ± 37.60 | -19.61 ± 35.60 | -24.31 ± 42.74 | -20.07 ± 31.20 | -18.23 ± 43.93 | -22.78 ± 36.27 |
| Change (%) at Week 16--Observed | -15.21 ± 36.90 | -29.70 ± 30.72 | -24.17 ± 44.61 | -20.22 ± 30.16 | -25.09 ± 54.31 | -22.46 ± 35.77 |
| Change (%) at Week 48--LOCF | -12.82 ± 40.33 | -30.75 ± 24.51 | -46.97 ± 39.90 | -9.31 ± 41.28 | -19.89 ± 90.61 | -25.54 ± 39.87 |
| Change (%) at Week 48--Observed | -21.81 ± 38.75 | -30.02 ± 34.39 | -63.04 ± 29.04 | -33.16 ± 15.48 | 84.98 ± 166.19 | -38.33 ± 36.22 |
The number of subjects who had a "Clear" or "Almost Clear" assessment, using the Physician Global Assessment Scale (PGA), at Week 16 of all subjects whether they completed 16 weeks or not (last observation carried forward \[LOCF\]) \[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.\]
| Participants | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | All Belumosudil |
|---|---|---|---|---|---|---|
| Efficacy: Number of Subjects With Clear or Almost Clear PGA at Week 16--LOCF | 1 | 0 | 2 | 1 | 2 | 4 |
The percentage (%) of subjects who had a "Clear" or "Almost Clear" assessment using the Physician Global Assessment Scale at Week 16 of belumosudil vs. placebo for all subjects whether they completed 16 weeks or not (last observation carried forward \[LOCF\]). \[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.\]
| Percentage (%) of subjects | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | All Belumosudil |
|---|---|---|---|---|---|
| Efficacy: Percentage of Subjects With Clear or Almost Clear PGA Comparing Belumosudil to Placebo at Week 16--LOCF | -6.8 (-23.5 to 10.0) | -11.1 (-25.6 to 3.4) | -1.6 (-20.8 to 17.6) | -7.3 (-23.6 to 9.0) | -6.8 (-21.9 to 8.3) |
Changes in mean Dermatology Life Quality Index (DLQI) score from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment). \[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. DLQI scoring as measured on subject's life: 0-1 = no effect; 2-5 = small effect; 6-10 = moderate effect; 11 to 20 = very large effect; 21 to 30 = extremely large effect. Change \< 0% is improvement; \> 0% is worsening. The total rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.\]
| Score on a scale | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | All Belumosudil |
|---|---|---|---|---|---|---|
| Baseline | 10.6 ± 6.3 | 16.5 ± 9.4 | 12.2 ± 6.5 | 11.0 ± 7.1 | 10.3 ± 6.4 | 12.5 ± 7.7 |
| Change at Week 16 | -2.2 ± 5.6 | -3.4 ± 4.0 | -2.5 ± 6.0 | -2.3 ± 7.0 | -4.0 ± 6.7 | -2.6 ± 5.7 |
| Change at Week 48 | -6.5 ± 5.1 | -1.0 ± 8.6 | -5.2 ± 6.9 | -3.7 ± 3.2 | -3.0 ± 2.8 | -4.7 ± 6.3 |
Mean percentage changes in Dermatology Life Quality Index (DLQI) from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment). \[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.\]
| Percentage change of DLQI score | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | All Belumosudil |
|---|---|---|---|---|---|---|
| Percentage Change at Week 16 | -5.73 ± 60.75 | -14.8 ± 28.78 | -22.22 ± 48.60 | -6.4 ± 79.95 | -40.30 ± 47.83 | -12.55 ± 56.58 |
| Percentage Change at Week 48 | -32.41 ± 86.97 | 3.54 ± 54.32 | -45.60 ± 45.84 | -53.73 ± 45.24 | -54.17 ± 41.25 | -33.11 ± 65.64 |
The number of subjects who had treatment-emergent adverse events (TEAEs), severity of TEAEs, relationship of TEAEs to study medication, serious TEAEs (SAEs), dose interruption, discontinuations, and deaths. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = Death. Related to study medication is defined as possible related, probable related, and related
| Participants | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | All Belumosudile |
|---|---|---|---|---|---|---|
| At least 1 TEAE | 14 | 13 | 14 | 16 | 11 | 57 |
| Grade 3 or Greater TEAE | 2 | 3 | 0 | 5 | 2 | 10 |
| Related TEAE | 8 | 6 | 5 | 9 | 6 | 28 |
| Related Grade 3 or Greater TEAE | 1 | 1 | 0 | 3 | 1 | 5 |
| Leading to Dose Interruption | 1 | 1 | 1 | 4 | 0 | 7 |
| SAE | 1 | 0 | 0 | 3 | 1 | 4 |
| Related SAE | 0 | 0 | 0 | 0 | 0 | 0 |
| Leading to Discontinuation | 6 | 1 | 1 | 7 | 3 | 15 |
| Deaths | 1 | 0 | 0 | 0 | 0 | 1 |
Collected over Approximately 52 weeks: up to 48 weeks of treatment and 30-day follow-up. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belumosudil 200 mg QD + Placebo | 1/23 (4.3%) | 1/23 (4.3%) | 14/23 (60.9%) |
| Belumosudil 200 mg BID (Twice Daily) + Placebo | 0/22 (0%) | 0/22 (0%) | 13/22 (59.1%) |
| Belumosudil 400 mg QD + Placebo | 0/21 (0%) | 0/21 (0%) | 14/21 (66.7%) |
| Belumosudil 600 mg/Day | 0/26 (0%) | 3/26 (11.5%) | 16/26 (61.5%) |
| Placebo | 0/18 (0%) | 1/18 (5.6%) | 11/92 (12%) |
| All Belumosudil | 1/92 (1.1%) | 1/92 (1.1%) | 57/92 (62%) |
| Event | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | All Belumosudil |
|---|---|---|---|---|---|---|
| HypercholesterolemiaMetabolism and nutrition disorders | 0/23 | 0/22 | 0/21 | 0/26 | 1/18 | 1/92 |
| Natural deathGeneral disorders | 1/23 | 0/22 | 0/21 | 0/26 | 0/18 | 1/92 |
| Chronic obstructive pulmonary disease (COPD)Respiratory, thoracic and mediastinal disorders | 0/23 | 0/22 | 0/21 | 1/26 | 0/18 | 1/92 |
| PneumoniaInfections and infestations | 0/23 | 0/22 | 0/21 | 1/26 | 0/18 | 0/92 |
| Thalamic infarctionNervous system disorders | 0/23 | 0/22 | 0/21 | 1/26 | 0/18 | 1/92 |
| Event | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | All Belumosudil |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/23 | 4/22 | 1/21 | 1/26 | 1/92 | 6/92 |
| InfluenzaInfections and infestations | 0/23 | 1/22 | 3/21 | 0/26 | 0/92 | 4/92 |
| Viral upper respiratory tract infectionInfections and infestations | 2/23 | 3/22 | 0/21 | 1/26 | 0/92 | 6/92 |
| Urinary tract infectionInfections and infestations | 0/23 | 0/22 | 2/21 | 1/26 | 1/92 | 3/92 |
| HeadacheNervous system disorders | 0/23 | 2/22 | 2/21 | 2/26 | 0/92 | 6/92 |
| PruritusSkin and subcutaneous tissue disorders | 0/23 | 1/22 | 2/21 | 1/26 | 1/92 | 4/92 |
| DyspepsiaGastrointestinal disorders | 0/23 | 2/22 | 0/21 | 0/26 | 0/92 | 2/92 |
| ContusionInjury, poisoning and procedural complications | 0/23 | 2/22 | 0/21 | 0/26 | 0/92 | 2/92 |
| Alanine aminotransaminase (ALT) increasedInvestigations | 2/23 | 0/22 | 1/21 | 2/26 | 2/92 | 5/92 |
| Hepatic enzyme increasedInvestigations | 2/23 | 1/22 | 0/21 | 2/26 | 1/92 | 5/92 |
| Age, Continuous(Years) | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 49.3 ± 8.9 | 46.2 ± 9.6 | 43.0 ± 11.4 | 43.5 ± 11.5 | 45.7 ± 14.2 | 45.5 ± 11.2 |
| Sex: Female, Male(Participants) | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 16 | 13 | 14 | 15 | 11 | 69 |
| Male | 7 | 9 | 7 | 11 | 7 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 4 | 8 | 2 | 23 |
| Not Hispanic or Latino | 18 | 18 | 16 | 18 | 15 | 85 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 2 | 1 | 1 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 1 | 2 | 1 | 3 | 8 |
| White | 20 | 19 | 17 | 24 | 14 | 94 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 2 |
| BMI (Mean)(kg/m^2) | Belumosudil 200 mg QD + Placebo | Belumosudil 200 mg BID (Twice Daily) + Placebo | Belumosudil 400 mg QD + Placebo | Belumosudil 600 mg/Day | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 33.8 ± 9.9 | 30.7 ± 7.0 | 29.9 ± 7.4 | 33.1 ± 10.7 | 32 ± 6.7 | 32.0 ± 8.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2016 to primary completion in Feb 2019, 28 months.
Results were first posted in Sep 2021, 2 years 7 months after primary completion. A results delay was requested in Apr 2020.
Of 42 industry-sponsored phase 2 interventional studies under Skin Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 19. This study's 28 months is above that.
Counting every sponsor, half of 57 studies reached it within 15 months; a quarter within 10 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belumosudil